RPCA
CLVS

Running Point Capital Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Running Point Capital Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,000
Closed -$12K – 239
2022
Q3 		$12K Hold
10,000
– – 0.01% 196
2022
Q2 		$18K Hold
10,000
– – 0.01% 190
2022
Q1 		$20K Buy
+10,000
New +$19.6K 0.01% 189

Other funds holding CLVS

IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $1.21B AUM 20.39% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
MAI Capital Management
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Wedbush Securities
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $163M AUM 15.03% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Running Point Capital Advisors's CLVS Position: Q4 2022 in Review

Running Point Capital Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 10,000 shares — an estimated $12K sold.

Running Point Capital Advisors first reported a position in CLVS in Q1 2022 and held it in 3 quarters. The position peaked at $20K in Q1 2022. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Running Point Capital Advisors reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Running Point Capital Advisors sold 10,000 Clovis Oncology, Inc. shares in Q4 2022, an estimated $12K.
  • Running Point Capital Advisors first reported a position in Clovis Oncology, Inc. in Q1 2022 and held it in 3 quarters.
  • Running Point Capital Advisors's Clovis Oncology, Inc. position peaked at $20K in Q1 2022.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Running Point Capital Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.